Skip to content
Open access

Intrinsically disordered regions in the NLRP family of receptors act as regulatory hubs for inflammasome condensation and activation

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 78 references
Medicine

TL;DR

A critical role is uncovered for intrinsically disordered regions (IDRs) in activating NLRP1, NLRP3, and NLRP14 inflammasomes, suggesting that targeting the dynamics of phase transitions could open novel therapeutic avenues for treating inflammatory and autoimmune diseases.

Abstract

Inflammasomes are multiprotein complexes that orchestrate immune responses to pathogenic and sterile insults by regulating the maturation of inflammatory cytokines and pyroptotic cell death. While inflammasome activation is well-characterized at the biochemical level, the mechanisms governing the spatial and temporal assembly of these complexes remain poorly understood. Here, we uncover a critical role for intrinsically disordered regions (IDRs) in activating NLRP1, NLRP3, and NLRP14 inflammasomes. Through structural prediction analyses, we identify IDRs within these receptors that harbor post-translational modification sites essential for inflammasome assembly and function. Notably, disease-associated mutations in NLRP1 and NLRP3 occur within these IDRs, underscoring their functional relevance in inflammatory disorders. Our computational analysis suggests that IDR-mediated phase separation may drive inflammasome condensation at the perinuclear membrane, serving as a sensor for cellular stress, as stress signals may change their conformation, through post-translational modifications, and thus their interaction capacity. Furthermore, inflammasomes lacking IDRs in their NLRPs may rely on interactions with chaperone or adapter proteins containing IDRs for proper assembly. These insights provide a new framework for understanding the regulation of inflammasomes, suggesting that targeting the dynamics of phase transitions could open novel therapeutic avenues for treating inflammatory and autoimmune diseases.

Read PDF

Similar papers

Open access Sep 2026

Structural mechanisms for ATP-mediated inhibition of human NLRP6 inflammasome.

Cryogenic-electron microscopy structures of human NLRP6 monomer in the adenosine-5'-triphosphate (ATP)/NBD-bound (twisted conformation) and unbound (extended conformation) states reveal the ATP-mediated cooperative inhibition mechanism of NLRP6 and provide insight into the therapeutic intervention of NLRP6-related auto...

Zhen Cui, Qi Sheng, Minsoo Son et al. · 0 citations
Sep 2026

NNV mediates the activation of the NLRP3 inflammasome through mtDNA release and oxidative DNA damage.

The NLRP3 inflammasome is a cytoplasmic multiprotein complex that is activated under stress or infection conditions. It promotes the maturation of IL-1β by cleaving pro-Caspase-1, thereby playing a critical role in host innate immune responses. Various viruses can differentially activate NLRP3 through distinct mechanis...

Li-Fang Cao, Run-Bin Huang, Lu Yang et al. · 0 citations
Aug 2026

Vilazodone inhibits NLRP3 inflammasome assembly by targeting the NACHT domain and alleviates inflammatory disease.

Vilazodone exerted anti-inflammatory effects in vivo, reducing cytokine production in mouse models of MSU-induced peritonitis and LPS-induced systemic inflammation and highlight its potential for repurposing in inflammasome-driven diseases.

Xiang-Yu Yang, Gui-Fang Xiong, Jie Yang et al. · 0 citations
Review Open access Sep 2026

The NLRP3 inflammasome at the crossroads of innate immune signaling and cell death

Recent advances in the understanding of the molecular mechanisms that mediate interactions between NLRP3 and other inflammasome-associated pathways are summarized, focusing on shared signaling components, organelle dynamics, posttranslational modifications, and feedback regulatory circuits.

Nan-Yang Xiao, Ze-Xuan Lu, D. Cooper et al. · 0 citations
Review Open access Sep 2026

The NLRP3 inflammasome in physiological and dysfunctional host response in human sepsis and critical illness: a narrative review

Although targeted modulation of inflammasome pathways represents a promising therapeutic strategy, further research is needed to refine patient selection, identify reliable biomarkers, and better characterise disease heterogeneity to enable successful clinical translation.

Caroline Neumann, Florian Hickl, Julia Kemnitzer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.